Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) and Omeros (NASDAQ:OMER – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Profitability
This table compares Guided Therapeutics and Omeros’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Guided Therapeutics | N/A | N/A | -274.24% |
| Omeros | N/A | -102.16% | 64.87% |
Valuation and Earnings
This table compares Guided Therapeutics and Omeros”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Guided Therapeutics | $770,000.00 | 36.36 | -$3.20 million | ($0.04) | -7.25 |
| Omeros | N/A | N/A | -$3.35 million | $0.70 | 18.88 |
Guided Therapeutics has higher revenue and earnings than Omeros. Guided Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations for Guided Therapeutics and Omeros, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Guided Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Omeros | 0 | 3 | 2 | 1 | 2.67 |
Omeros has a consensus target price of $38.00, indicating a potential upside of 187.55%. Given Omeros’ stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Guided Therapeutics.
Volatility and Risk
Guided Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500.
Summary
Omeros beats Guided Therapeutics on 9 of the 13 factors compared between the two stocks.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
